Treatment of Mild-to-Moderate Ulcerative Colitis

Target Audience: Gastroenterologists, primary care providers

Target Population: Patients with mild-to-moderate ulcerative colitis

Background and Objective

Updated treatment recommendations for patients with mild-to-moderate ulcerative colitis are based on evidence from the literature using GRADE methodology and best practices of the Institute of Medicine.

Key Recommendations

• Higher-dose mesalamine (2–4 grams) rather than lower dose should be used for patients with active symptoms.

• Once-daily mesalamine is preferred over multiple-dosing regimens.

• Mesalamine is preferred over budesonide for mild-to-moderate disease.

• There is currently no evidence to support the use of probioti…